CSPC Pharmaceutical Group Limited (CVG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CSPC Pharmaceutical Group Limited (CVG) has a cash flow conversion efficiency ratio of 0.104x as of June 2020. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.16 Billion ≈ $2.52 Billion USD) by net assets (€20.71 Billion ≈ $24.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can CSPC Pharmaceutical Group Limited fund operations to measure how many days the company can operate on defensive assets alone.
CSPC Pharmaceutical Group Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how CSPC Pharmaceutical Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CSPC Pharmaceutical Group Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CSPC Pharmaceutical Group Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
D'Ieteren Group SA
BR:DIE
|
-0.738x |
|
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
|
0.002x |
|
James Hardie Industries plc
F:JHA
|
0.031x |
|
Gildan Activewear Inc.
TO:GIL
|
-0.081x |
|
Yangzhou Yangjie Electronic Technology Co Ltd
SHE:300373
|
0.026x |
|
Allison Transmission Holdings Inc
NYSE:ALSN
|
0.082x |
|
Barito Pacific Tbk
JK:BRPT
|
0.043x |
|
China Eastern Airlines Corp Ltd
SHG:600115
|
0.399x |
Annual Cash Flow Conversion Efficiency for CSPC Pharmaceutical Group Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of CSPC Pharmaceutical Group Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of CSPC Pharmaceutical Group Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €34.55 Billion ≈ $40.39 Billion |
€5.83 Billion ≈ $6.82 Billion |
0.169x | +26.06% |
| 2024-12-31 | €33.87 Billion ≈ $39.59 Billion |
€4.53 Billion ≈ $5.30 Billion |
0.134x | +12.21% |
| 2023-12-31 | €35.02 Billion ≈ $40.94 Billion |
€4.18 Billion ≈ $4.89 Billion |
0.119x | -50.49% |
| 2022-12-31 | €31.64 Billion ≈ $36.99 Billion |
€7.63 Billion ≈ $8.92 Billion |
0.241x | +39.47% |
| 2021-12-31 | €26.83 Billion ≈ $31.37 Billion |
€4.64 Billion ≈ $5.42 Billion |
0.173x | -40.76% |
| 2020-12-31 | €23.10 Billion ≈ $27.01 Billion |
€6.74 Billion ≈ $7.88 Billion |
0.292x | +50.49% |
| 2019-12-31 | €19.52 Billion ≈ $22.82 Billion |
€3.78 Billion ≈ $4.42 Billion |
0.194x | -20.83% |
| 2018-12-31 | €15.50 Billion ≈ $18.12 Billion |
€3.80 Billion ≈ $4.44 Billion |
0.245x | -4.12% |
| 2017-12-31 | €12.87 Billion ≈ $15.05 Billion |
€3.29 Billion ≈ $3.84 Billion |
0.255x | -20.08% |
| 2016-12-31 | €9.13 Billion ≈ $10.67 Billion |
€2.92 Billion ≈ $3.41 Billion |
0.320x | +25.21% |
| 2015-12-31 | €8.81 Billion ≈ $10.30 Billion |
€2.25 Billion ≈ $2.63 Billion |
0.255x | +15.17% |
| 2014-12-31 | €8.15 Billion ≈ $9.53 Billion |
€1.81 Billion ≈ $2.11 Billion |
0.222x | +106.60% |
| 2013-12-31 | €7.60 Billion ≈ $8.88 Billion |
€814.86 Million ≈ $952.66 Million |
0.107x | -- |
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more